Overview
- President Trump announced on Monday, Aug. 31 that nine mid‑sized manufacturers — Alcon, Astellas, BeOne, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva and UCB — joined the administration’s voluntary most‑favored‑nation (MFN) drug‑pricing deals, bringing total signatories to 26.
- The White House said the agreements give every state Medicaid program access to MFN prices and include at least $19.6 billion in near‑term U.S. manufacturing commitments plus donations of active ingredients to a Strategic Active Pharmaceutical Ingredients Reserve (SAPIR).
- Officials projected roughly $600 billion in savings over a decade and cited more than $700 million in consumer savings from the TrumpRx portal, though the deals are voluntary and the administration has not published the full contract terms or detailed price lists.
- Experts and consumer groups note Medicaid already receives large statutory rebates, so the MFN deals mainly change government spending and may not lower most insured patients’ copays, and analysts warn companies could respond by altering foreign launches or prices.
- The expansion was secured through trade incentives and tariff concessions in return for pricing and onshoring pledges, and watchdogs including Public Citizen are pressing for the contracts to be released or for Congress to codify the program to lock in terms.